Skip to content

AnaptysBio, Inc. ANAB Free cash flow

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Eli Lilly logo
Eli LillyLLY
$3.01B+1,828%
Pfizer logo
PfizerPFE
$2.18B+23.0%
Amgen logo
AmgenAMGN
$1.48B+50.7%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
Biogen logo
BiogenBIIB
$594.3M+167%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Calculated from AnaptysBio, Inc.’s reported figures.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s free cash flow?
AnaptysBio, Inc. (ANAB) reported free cash flow of -$25.94M in Q1 2026.
How has AnaptysBio, Inc.'s free cash flow changed year-over-year?
AnaptysBio, Inc.'s free cash flow decreased by 141.6% year-over-year, from -$10.74M to -$25.94M.
What is the long-term trend for AnaptysBio, Inc.'s free cash flow?
Over 3 years (2022 to 2025), AnaptysBio, Inc.'s free cash flow has grown at a -35.8% compound annual growth rate (CAGR), from -$73.95M to $19.61M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.